Dapoxetine tablet is only indicated in men with premature ejaculation. Concomitant treatment with other SSRIs, SNRIs, TCAs, MAOIs, thioridazine or any of the herbal products should not be administered within 7 days after dapoxetine has been discontinued. Although recent guidelines recommend to treat ED first in men with both PE and ED, this recommendation is not based on evidence and there are limited data about the ef cacy and safety of. The Pan Mersey Area Prescribing Committee recommends the prescribing of DAPOXETINE tablets (Priligy®) for the treatment of premature ejaculation when recommended by a psychosexual service or a specialist clinician with experience of treating psychosexual disorders. Dapoxetine is a potent selective serotonin reuptake inhibitor (SSRI) with an IC50 of 1.12 nM, while its major human metabolites, desmethyldapoxetine (IC50 1.0 nM) and didesmethyldapoxetine (IC50 = 2.0 nM) are equivalent or less potent (dapoxetine-N-oxide (IC50 = 282 nM)). Priligy is used to treat premature ejaculation, in men between 18 and 64 years old. Premature ejaculation is a common sexual problem. It is when a man ejaculates with little sexual stimulation and before the man wants to. This can cause problems for the man and may cause problems in sexual relationships. A clinical study conducted to compare the pharmacokinetics of dapoxetine in Japanese and Caucasian subjects showed 10% to 20% higher plasma levels (AUC and peak concentration) of dapoxetine in Japanese subjects due to lower body weight. Dapoxetine should be administered only as on-demand treatment before anticipated sexual activity. Dapoxetine should not be prescribed to delay ejaculation in men who have not been diagnosed with PE.